至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca2+ dependent allosteric binding site

Nature Communications. 2025-05; 
Leslie A Dakin, Li Xing, Justin Hall, Weidong Ding, Felix F Vajdos, Jeffrey W Pelker, Simeon Ramsey, Paul Balbo, Parag V Sahasrabudhe, Mary Ellen Banker, Won Young Choi, Stephen W Wright, Jeanne S Chang, John M Curto, Jennifer E Davoren, Susan E Drozda, Kimberly F Fennell, Kentaro Futatsugi, Steve Kortum, Katherine L Lee, Shenping Liu, Frank Lovering, Jennifer A Nicki, John I Trujillo, Fabien Vincent, Mark E Schnute Medicine Design, Pfizer Inc, Cambridge, MA, USA.
Products/Services Used Details Operation
Gene Synthesis A codon-optimized sequence encoding full-length PAD4 with an N-terminal fusion of Avitag-His6-FLAG tags, followed by a PreScission Protease site, was cloned into pET28b(+) by Genscript. Get A Quote

摘要

Peptidylarginine deiminases (PAD1-4) are calcium dependent enzymes responsible for protein citrullination, a post-translational modification converting arginine residues to citrulline. Elevated levels of citrullinated proteins have been associated with rheumatoid arthritis, neurodegenerative diseases, and cancers. Though highly selective PAD4 inhibitors have been described, inhibitors to the broader family currently are limited to covalent substrate analogs. Herein, we describe an allosteric binding pocket common to PAD1-4 suitable for the identification of potent, non-covalent enzyme inhibitors. A ligand-based virtual screen is utilized to identify a PAD4 inhibitor for which surface plasmon resonance confirms ... More

关键词